Study of Celecoxib Bioavailability in Healthy Subjects
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT00296127
Collaborator
(none)
24
1
28
26.1
Study Details
Study Description
Brief Summary
To evaluate the bioavailability of celecoxib administered as capsule contents sprinkled onto applesauce relative to intact capsule
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Relative Bioavailability Study Of Celecoxib Administered As Capsule Contents Sprinkled On Applesauce In Healthy Adult Volunteers
Study Start Date
:
Feb 1, 2006
Study Completion Date
:
Mar 1, 2006
Outcome Measures
Primary Outcome Measures
- Relative bioavailability of celecoxib administered as capsule contents sprinkled onto applesauce relative intact capsule after a single dose []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- Healthy male and/or female subjects
Exclusion Criteria:
- Standard criteria for healthy volunteer studies
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Pfizer Investigational Site | New Haven | Connecticut | United States | 06511-5473 |
Sponsors and Collaborators
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
ClinicalTrials.gov Identifier:
NCT00296127
Other Study ID Numbers:
- A3191202
First Posted:
Feb 24, 2006
Last Update Posted:
Mar 3, 2021
Last Verified:
Mar 1, 2021
Additional relevant MeSH terms: